Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H19N3O6S.H2O |
| Molecular Weight | 423.44 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=CC=C3)C(O)=O
InChI
InChIKey=FFOHOZBDRVVZIM-PFBPGKLMSA-N
InChI=1S/C18H19N3O6S.H2O/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10;/h2-6,12-13,17H,7-8,19H2,1H3,(H,20,23)(H,25,26);1H2/t12-,13-,17-;/m1./s1
Cephaloglycin, first oral cephalosporin, was introduced in 1965, but is no longer in common use. It is an orally absorbed derivative of cephalosporin C. Cephaloglycin binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4887297/ |
0.5 g single, oral dose: 0.5 g route of administration: Oral experiment type: SINGLE co-administered: |
CEPHALOGLYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4887297/ |
0.5 g single, oral dose: 0.5 g route of administration: Oral experiment type: SINGLE co-administered: |
CEPHALOGLYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4887297/ |
0.5 g single, oral dose: 0.5 g route of administration: Oral experiment type: SINGLE co-administered: |
CEPHALOGLYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
75% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4887297/ |
0.5 g single, oral dose: 0.5 g route of administration: Oral experiment type: SINGLE co-administered: |
CEPHALOGLYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Drugs as allergens: an immunoassay for detecting IgE antibodies to cephalosporins. | 1990 |
|
| Plasma glutathione peroxidase and its relationship to renal proximal tubule function. | 1998 Nov |
|
| Treating critical illness: the importance of first doing no harm. | 2005 Jun |
|
| Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project. | 2010 |
|
| Protein engineering of penicillin acylase. | 2010 Jul |
Patents
Sample Use Guides
Each subject received a
single oral dose of each of the following: 250, 500,
and 1,000 mg of cephaloglycin after an overnight fast
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
70610481
Created by
admin on Fri Dec 15 15:08:11 GMT 2023 , Edited by admin on Fri Dec 15 15:08:11 GMT 2023
|
PRIMARY | |||
|
KR2KCF5IBM
Created by
admin on Fri Dec 15 15:08:11 GMT 2023 , Edited by admin on Fri Dec 15 15:08:11 GMT 2023
|
PRIMARY | |||
|
DBSALT001840
Created by
admin on Fri Dec 15 15:08:11 GMT 2023 , Edited by admin on Fri Dec 15 15:08:11 GMT 2023
|
PRIMARY | |||
|
22202-76-2
Created by
admin on Fri Dec 15 15:08:11 GMT 2023 , Edited by admin on Fri Dec 15 15:08:11 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
